biostudies-literatureUnknown30(10)Fabi ADompé farmaceutici S.p.A., Milan, Italy<h4>Background</h4>Cancer-related fatigue (CRF) is a common symptom in patients with locally advanced or metastatic breast cancer (LA/M BC) receiving taxane-based chemotherapy (CT). CRF is commonly assessed as a subjective experience by patient questionnaires, such as the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue. The aim of this study was to extend the validity of the FACIT-Fatigue and estimate clinically meaningful group-level differences in this patient population.<h4>Materials and methods</h4>This was a prospective, noninterventional, multinational study conducted in the United States and Italy from October 2021 to August 2023 in adult patients with LA/M BC eligible to receive cycle 1 of taxane-based CT. Patients completed a FACIT-Fatigue survey before starting CThe oncologistoyaf292https://www.ebi.ac.uk/biostudies/studies/S-EPMC12573256biostudies-literatureValidation of the FACIT-Fatigue scale in patients with locally advanced or metastatic breast cancer.PMC12573256Minnella EMAllegretti MGavioli EMFabi ALourdes LWakade RGandini CHager SfalseValidation of the FACIT-Fatigue scale in patients with locally advanced or metastatic breast cancer.<h4>Background</h4>Cancer-related fatigue (CRF) is a common symptom in patients with locally advanced or metastatic breast cancer (LA/M BC) receiving taxane-based chemotherapy (CT). CRF is commonly assessed as a subjective experience by patient questionnaires, such as the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue. The aim of this study was to extend the validity of the FACIT-Fatigue and estimate clinically meaningful group-level differences in this patient population.<h4>Materials and methods</h4>This was a prospective, noninterventional, multinational study conducted in the United States and Italy from October 2021 to August 2023 in adult patients with LA/M BC eligible to receive cycle 1 of taxane-based CT. Patients completed a FACIT-Fatigue survey before starting C2025-01-01T00:00:00Z2025 Oct2026-06-05T09:40:02.386Z2026-05-15T03:11:59.923ZS-EPMC125732564100606810.1093/oncolo/oyaf292